Fig 1: Serial serum concentrations of S100A9 and TNC. (A) Serum S100A9 levels before surgery, after surgery and during relapse in CRC patients (n=21). (B) Serum TNC levels before surgery, after surgery and during relapse in CRC patients (n=21).
Fig 2: TNC was related to GAM cell infiltration in LGGs (A) Kaplan-Meier survival analysis showing that the infiltration level of macrophages, M1-like cells, and M2-like cells with the prognosis of LGG patients in the TIMER database using the XCELL method. (** p < 0.01; *** p < 0.001; **** p < 0.0001) (B) The scatter plot indicating the correlation between TNC expression level (log2TPM) and the infiltration level of macrophages, M1-like cells, and M2-like cells in LGG patients using the TIMER database. (*** p<0.001) (C) qRT-PCR analysis of Iba1 and CD11b mRNA expression in 32 patients grouped by TNC mRNA level. (* p < 0.05; *** p < 0.001) (D) IF staining of TNC (green) and Iba1 (red) in human LGG samples. Representative images are shown. (Scale bars = 200 um) (s) MRI images of patients with grade II (E) and grade III (F) gliomas.(n=16) (G) Immunoblotting of TNC and CD11b in grade II and III glioma patients sorted by CD11b mRNA level. (The samples correspond to the patients in (E, F).
Fig 3: ROC curve analysis of serum concentrations from patients with CRC and controls. (A) ROC curves of S100A9, TNC, CEA and CA19-9 levels as screening biomarkers of CRC. (B) ROC curves of S100A9, TNC, CEA and CA19-9 levels as biomarkers differentiating between CRC and BCD. (C) The AUC performance of the following combinations of serum concentrations: S100A9 and TNC; CEA and CA19-9; and S100A9, TNC and CEA.
Fig 4: Serum S100A9 and TNC concentrations in colorectal cancer patients, benign colonic disease patients and healthy donors. The comparison of serum S100A9 (A) or TNC (B) levels in CRC patients, benign colonic disease (BCD) patients and healthy donors are shown as dot plots, and the middle line represents the median (p<0.001). Panels (C) and (D) show S100A9 and TNC levels, respectively, in BCD patients and patients with different CRC stages. The three lines in each scatter plot indicate the median and quartiles of this set of data. Abbreviations: CRC: colorectal cancer patients BCD: benign colonic disease patients HD: healthy donors NS: not statistically significant
Fig 5: TNC was associated with LGGs immune microenvironment (A) Functional gene-set enrichment analysis of TNC used TCGA transcriptome data. (B) Histogram describing the level of immune cell infiltration as calculated by using the ImmuCellAI theory in different TNC expression groups. (*** p < 0.001, ns, not significant) (C) qRT-PCR analysis of mRNA expression of CD4 and CD8 and TNC in 32 LGG specimens grouped by TNC mRNA level. (* p < 0.05; ** p < 0.01; *** p < 0.001) (D, E) IHC staining of TNC, tumor-associated macrophages markers (CD68 and CD206), and T cell markers (CD4 and CD8) in grade II (D) and grade III (E) LGG specimens. Representative images are shown. (Scale bars = 200 um) (F) Scatter plot showing the distribution of CD68, CD206, CD4 and CD8 IHC scores (H-SCORE) in the two subgroups grouped based on the median of the TNC staining score. (* p < 0.05; ** p < 0.01; ***p < 0.001, ****p < 0.0001, n = 30) (G) The forest plot showing the single-factor logistic regression analysis of the prognosis of TNC in TCGA pan-cancer data. (LGG: HR=1.66) (H) Kaplan-Meier curve depicting the clinical value of TNC in 30 LGG patients with follow-up information. (* p < 0.05).
Supplier Page from CUSABIO Technology LLC for Human Tenascin-c (TNC) ELISA Kit